Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Palumbo, Antônio; Bringhen, Sara; Larocca, Alessandra; Rossi, Davide; Raimondo, Francesco Di; Magarotto, Valeria; Patriarca, Francesca; Levi, Anna; Benevolo, Giulia; Vincelli, Iolanda Donatella; Grasso, Mariella; Franceschini, Luca; Gottardi, Daniela; Zambello, Renato; Montefusco, Vittorio; Falcone, Antonietta; Omedè, Paola; Marasca, Roberto; Morabito, Fortunato; Mina, Roberto; Guglielmelli, Tommasina; Nozzoli, Chiara; Passera, Roberto; Gaïdano, Gianluca; Offidani, Massimo; Ria, Roberto; Petrucci, Maria Teresa; Musto, Pellegrino; Boccadoro, Mario; Cavo, Michèle

doi:10.1200/jco.2013.52.0023

Cited by 197 publications

(151 citation statements)

References 32 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…1 In this regard, the therapeutic approach to earlier-stage multiple myeloma has changed substantially in recent decades. [2][3][4][5][6][7][8][9][10][11] However, the current belief is that even with aggressive therapy, the risk of progression to ESRD is high, recovery of renal function is low, and survival time on dialysis therapy is very short. 12 As the detection and treatment of multiple myeloma continues to evolve, it seems natural to question whether reductions in associated ESRD have occurred, and if so, among which demographic subgroups.…”

mentioning

confidence: 99%

ESRD due to Multiple Myeloma in the United States, 2001–2010

Reule

Sexton

Solid

et al. 2015

JASN

View full text Add to dashboard Cite

Although management of multiple myeloma has changed substantially in the last decade, it is unknown whether the burden of ESRD due to multiple myeloma has changed, or whether survival of patients with multiple myeloma on RRT has improved. Regarding ESRD due to multiple myeloma necessitating RRT in the United States, we evaluated temporal trends between 2001 and 2010 for demography-adjusted incidence ratios, relative to rates in [2001][2002], and mortality hazards from RRT initiation, relative to hazards in [2001][2002]. In this retrospective cohort study, we used the US Renal Data System database (n=1,069,343), 2001-2010, to identify patients with ESRD due to multiple myeloma treated with RRT (n=12,703). Demography-adjusted incidence ratios of ESRD from multiple myeloma decreased between 2001-2002 and 2009-2010 in the overall population (demography-adjusted incidence ratio 0.82; 95% confidence interval, 0.79 to 0.86) and in most demographic subgroups examined. Mortality rates were 86.7, 41.4, and 34.4 per 100 person-years in the first 3 years of RRT, respectively, compared with 32.3, 20.6, and 21.3 in matched controls without multiple myeloma. Unadjusted mortality hazards ratios declined monotonically after 2004 to a value of 0.72; 95% confidence interval, 0.67 to 0.77 in 2009-2010, and declines between 2001-2002 and 2008-2009 were observed (P,0.05) in most demographic subgroups examined. Findings were similar when adjustment was made for demographic characteristics, comorbidity markers, and laboratory test values. These data suggest the incidence of RRT from multiple myeloma in the United States has decreased in the last decade, and clinically meaningful increases in survival have occurred for these patients.

show abstract

mentioning

confidence: 99%

ESRD due to Multiple Myeloma in the United States, 2001–2010

Reule

Sexton

Solid

et al. 2015

JASN

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8] Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance therapy, 4-6 but others have reported improved PFS with no corresponding improvement in OS. [1][2][3] The lack of OS benefit may be due to crossover and insufficient follow-up, as well as the fact that these trials were not powered to detect differences in OS between treatment groups.…”

mentioning

confidence: 99%

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The PFS varied from 31-37 months versus 24 months for the VISTA trial. The median cumulative bortezomib dose delivered was similar in these trials, 20,21 indicating that a lower dose in induction treatment reduces discontinuation rate allowing for longer treatment.…”

mentioning

confidence: 68%